Cepheid

Sunnyvale, United States Founded: 1996 • Age: 30 yrs Acquired By Danaher
Developer of molecular diagnostic testing solutions
Annual revenue $54.9M Latest available
Total funding $19.1M 8 rounds
Employees 208 Tracked headcount
Investors 12 Known backers
Products - Services tracked
Competitors 10 Brand Intelligence

About Cepheid

Cepheid is a company based in Sunnyvale (United States) founded in 1996 was acquired by Danaher in September 2016. Cepheid has raised $19.1 million across 8 funding rounds from investors including Medtronic, NIH and Danaher. The company has 208 employees as of April 07, 2024. Cepheid has completed 1 acquisition, including OncoMark. Cepheid operates in a competitive market with competitors including Beckman Coulter, Blackrock Neurotech, Bruker, Complete Genomics and Esco Lifesciences, among others.

  • Headquarter Sunnyvale, United States
  • Employees 208 as on 07 Apr, 2024
  • Stage Public
  • Sectors
    Healthcare
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name Cepheid India Private Limited
  • Date of Incorporation 22 Aug, 2013
  • Jurisdiction Gurugram, Haryana, India
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research Unlock Sub-Sector Unlock Segment
Healthcare → Biotechnology, Genomics & Life Sciences Research Unlock Sub-Sector Unlock Segment
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    $54.88 M (USD)
    10.43
    as on Mar 31, 2022
  • Net Profit
    $7.33 M (USD)
    4.46
    as on Mar 31, 2022
  • EBITDA
    $10.37 M (USD)
    6.35
    as on Mar 31, 2022
  • Total Equity Funding
    $19.1 M (USD)

    in 8 rounds

  • Latest Funding Round
    $28 M (USD), Grant

    Jul 30, 2021

  • Investors
    Medtronic

    & 11 more

  • Employee Count
    208

    as on Apr 07, 2024

  • Investments & Acquisitions
  • Acquired by
    Danaher

    (Sep 06, 2016)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

People of Cepheid

Headcount 1000-5000
Employee Profiles 662
Employee Profiles
People
Dean Henderson
Global Purchasing Director
People
Christopher Delgado
Principal Industrial Designer
People
Doug Hasegawa
Senior Diagnostic Consumables Engineer
People
Kim Gilonske
Vice President, Commercial Solutions

Unlock access to complete

Funding Insights of Cepheid

Cepheid has successfully raised a total of $19.1M across 8 strategic funding rounds. The most recent funding activity was a Grant round of $28 million completed in July 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in Cepheid

Cepheid has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include Medtronic, NIH and Danaher.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Tech-based companies are invested in by Wheatley Partners.
Locked Locked Locked
Biotechnology investments are targeted by the venture capital firm.
Locked Locked Locked
PE firm investing in the US
Locked Locked Locked
Premium access

Investor details for Cepheid

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Cepheid

Cepheid has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include OncoMark.

Investments
Premium access

Investment portfolio details for Cepheid

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Acquisitions
Company Name Description Domain Location Founded Year Amount
Tissue-based cancer diagnostics are developed by OncoMark.
Locked Locked 2011 Locked
Premium access

Complete acquisition details for Cepheid

Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.

  • Transaction dates
  • Acquired stakes
  • Disclosed values
  • Domains and locations

Verified entity values are shown only after access is granted.

Financial Statements - Cepheid

Premium access

Detailed financials for Cepheid

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Cepheid Comparisons

Cepheid Primary company
Description
Developer of molecular diagnostic testing solutions
Location
Sunnyvale, United States
Founded Year
1996
Annual Revenue
$54.88 M (USD)
Net Profit
$7.33 M (USD)
EBITDA
$10.37 M (USD)
Employees
208
As of 2024
Premium access

Peer comparison for Cepheid

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Cepheid

Cepheid operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Beckman Coulter, Blackrock Neurotech, Bruker, Complete Genomics and Esco Lifesciences, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Provider of products for biomedical testing for R&D, diagnostic and commercial applications
Locked Locked Locked
Medical devices for neurological therapies are developed.
Locked Locked Locked
Diversified research instrument systems are manufactured and supplied.
Locked Locked Locked
DNA sequencing platform for human genome analysis is developed.
Locked Locked Locked
Manufacturer of biopharma equipment & IVF medical devices, and service provider for life science tools
Premium access

Detailed competitors of Cepheid

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Cepheid

Premium access

Complete news archive for Cepheid

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Cepheid

Cepheid was founded in 1996 and raised its 1st funding round 4 years after it was founded.

Cepheid is headquartered in Sunnyvale, United States. It is registered at Sunnyvale, California, United States.

Cepheid is a funded company, having raised a total of $19.1M across 8 funding rounds to date.

As of Apr 07, 2024, the latest employee count at Cepheid is 208.

Annual revenue of Cepheid is $54.88M as on Mar 31, 2022.

Cepheid was founded in 1996 in Sunnyvale, United States, within the molecular diagnostics sector. Testing solutions are provided across categories including hospital-acquired infections, critical infectious diseases such as multi-drug resistant tuberculosis, influenza, respiratory syncytial virus, and enteroviral meningitis, as well as sexual health and genetic assessments like a 30-minute test for thrombosis risk. Operations focus on healthcare applications in the United States.

Cepheid's top competitors include Blackrock Neurotech, Agilent and Esco Lifesciences.

Cepheid has made 1 acquisition, including OncoMark.

Cepheid has 12 investors. Key investors include Medtronic, NIH, Danaher, HHS, and DARPA.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available